Salud financiera de hoja de balance de Cell Impact

Salud financiera controles de criterios 3/6

Cell Impact tiene un patrimonio de los accionistas total de SEK257.8M y una deuda total de SEK17.7M, lo que sitúa su ratio deuda-patrimonio en 6.9%. Sus activos y pasivos totales son SEK306.9M y SEK49.1M respectivamente.

Información clave

6.9%

Ratio deuda-patrimonio

SEK 17.68m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	SEK 18.17m
Patrimonio	SEK 257.79m
Total pasivo	SEK 49.08m
Activos totales	SEK 306.87m

Actualizaciones recientes sobre salud financiera

Health Check: How Prudently Does Cell Impact (STO:CI) Use Debt?

May 13

Is Cell Impact (STO:CI) Using Debt In A Risky Way?

Jan 14

Here's Why We're Not Too Worried About Cell Impact's (STO:CI B) Cash Burn Situation

May 09

Recent updates

Health Check: How Prudently Does Cell Impact (STO:CI) Use Debt?

May 13

Is Cell Impact (STO:CI) Using Debt In A Risky Way?

Jan 14

Here's Why We're Not Too Worried About Cell Impact's (STO:CI B) Cash Burn Situation

May 09

Investors Who Bought Cell Impact (STO:CI B) Shares Three Years Ago Are Now Up 428%

Feb 21

How Much Is Cell Impact AB (publ) (STO:CI B) Paying Its CEO?

Dec 27

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (SEK93.8M) de CI superan a sus pasivos a corto plazo (SEK24.5M).

Pasivo a largo plazo: Los activos a corto plazo de CI (SEK93.8M) superan a sus pasivos a largo plazo (SEK24.6M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: CI tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de CI ha crecido de 1.8% a 6.9% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: CI tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: CI tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 22.1% cada año

Salud financiera de hoja de balance de Cell Impact

Salud financiera controles de criterios 3/6

Información clave

Actualizaciones recientes sobre salud financiera

Health Check: How Prudently Does Cell Impact (STO:CI) Use Debt?

Is Cell Impact (STO:CI) Using Debt In A Risky Way?

Cell Impact AB (publ) PUBL SHARE AK B to Be Deleted from Other OTC

Here's Why We're Not Too Worried About Cell Impact's (STO:CI B) Cash Burn Situation

Recent updates

Cell Impact AB (publ) to Report Fiscal Year 2024 Final Results on Mar 20, 2025

Chairman of the Board exercised options to buy kr76k worth of stock.

Cell Impact AB (Publ) Announces Daniel Vallin as the Permanent CEO, Effective from October 1, 2024

Director recently bought kr125k worth of stock

Second quarter 2024 earnings released

Cell Impact AB (Publ) Provides Earnings Guidance for the Year 2027 and 2030

Cell Impact Adds Sealing as A New Part of Production Process

New major risk - Share price stability

First quarter 2024 earnings released: kr0.04 loss per share (vs kr0.40 loss in 1Q 2023)

Cell Impact AB (Publ) Announces Board and Committee Changes

Director recently bought kr91k worth of stock

Full year 2023 earnings released: kr1.11 loss per share (vs kr1.38 loss in FY 2022)

Cell Impact AB (Publ) Appoints Henrik Jackman as Chief Application Engineer

Chief Executive Officer recently bought kr50k worth of stock

Cell Impact AB (publ) Announces CEO Changes

New major risk - Shareholder dilution

Cell Impact AB (Publ) Announces That Stefan Axellie to Leave Role as CFO

Third quarter 2023 earnings released: kr0.33 loss per share (vs kr0.38 loss in 3Q 2022)

Cell Impact AB (Publ) Announces Preliminary Earnings Guidance for Third Quarter 2023

New major risk - Market cap size

Cell Impact AB (publ) Announces Anna Frick Will Leave the Board

Chief Executive Officer recently bought kr101k worth of stock

Cell Impact AB (publ) Provides Earnings Guidance for the Year 2025 and 2028

Cell Impact AB (Publ) Announces Outstanding Measuring Precision Enabling Customers' Product Development

New major risk - Share price stability

Chief Executive Officer recently bought kr50k worth of stock

Health Check: How Prudently Does Cell Impact (STO:CI) Use Debt?

Full year 2022 earnings released: kr1.38 loss per share (vs kr1.35 loss in FY 2021)

Cell Impact AB (publ) to Report Fiscal Year 2023 Results on Mar 24, 2024

Is Cell Impact (STO:CI) Using Debt In A Risky Way?

No independent directors

Third quarter 2022 earnings released: kr0.38 loss per share (vs kr0.25 loss in 3Q 2021)

Second quarter 2022 earnings released

Cell Impact AB (publ) PUBL SHARE AK B to Be Deleted from Other OTC

First quarter 2022 earnings released

No independent directors

Full year 2021 earnings released: kr1.35 loss per share (vs kr0.88 loss in FY 2020)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Cell Impact AB (publ) to Report Q2, 2022 Results on Aug 25, 2022

Third quarter 2021 earnings released

Second quarter 2021 earnings released

Here's Why We're Not Too Worried About Cell Impact's (STO:CI B) Cash Burn Situation

First quarter 2021 earnings released

Cell Impact AB (publ) Receives SEK 42 Million Order from Plug Power for New Production Line and Flow Plates

Investors Who Bought Cell Impact (STO:CI B) Shares Three Years Ago Are Now Up 428%

Full year 2020 earnings released: kr0.85 loss per share (vs kr1.45 loss in FY 2019)

New 90-day high: kr49.70

Cell Impact Appoints Forrest Zhang as Country Manager in China, Effective May 3, 2021

How Much Is Cell Impact AB (publ) (STO:CI B) Paying Its CEO?

New 90-day high: kr29.30

New 90-day high: kr29.00

Third quarter 2020 earnings released: kr0.12 loss per share

New 90-day low: kr21.35

Cell Impact AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 175 million.

First half earnings released

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera